|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.28 EUR | +0.27% |
|
+5.18% | -39.68% |
| Dec. 10 | Bayer: new analyses on heart failure | CF |
| Dec. 10 | Investors cash in on some Dax favorites | DP |
| Capitalization | 19.93B 20.98B 18.51B 16.43B 29.74B 1,781B 32.88B 230B 84.83B 731B 78.81B 77.05B 3,188B | P/E ratio 2024 * |
-81.7x | P/E ratio 2025 * | 8.74x |
|---|---|---|---|---|---|
| Enterprise value | 52.24B 55B 48.52B 43.06B 77.96B 4,669B 86.18B 603B 222B 1,916B 207B 202B 8,356B | EV / Sales 2024 * |
1.13x | EV / Sales 2025 * | 1.06x |
| Free-Float |
100% | Yield 2024 * |
0.54% | Yield 2025 * | 0.54% |
More valuation ratios
* Estimated data
More news
Last Transcript: Bayer AG
| BAYER AG : UBS is Neutral | Dec. 09 | ZD |
| BAYER AG : JP Morgan reaffirms its Neutral rating | Dec. 03 | ZD |
| BAYER AG : DZ Bank reiterates its Buy rating | Nov. 27 | ZD |
| BAYER AG : UBS sticks Neutral | Nov. 21 | ZD |
| Jefferies lowers target for Bayer to 22 euros - 'Hold' | Nov. 20 | DP |
More press releases
More news
| 1 day | +0.27% | ||
| 1 week | +5.18% | ||
| Current month | +4.63% | ||
| 1 month | -15.76% | ||
| 3 months | -29.27% | ||
| 6 months | -27.79% | ||
| Current year | -39.68% |
1 week
19.01
20.55
1 month
18.4124.60
Current year
18.4136.09
1 year
18.4136.09
3 years
18.4167.99
5 years
18.4178.34
10 years
18.41146.45
| Director | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 58 | 2023-05-31 |
| Director of Finance/CFO | 55 | 2018-05-31 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 57 | 2021-01-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 68 | 2002-03-31 |
André van Broich
BRD | Director/Board Member | 54 | 2012-03-31 |
| Director/Board Member | 65 | 2022-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | ||
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | +60.94% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.27% | +5.18% | -36.40% | -55.70% | 21.03B | ||
| -0.50% | -0.03% | +33.70% | +229.18% | 724B | ||
| +0.03% | +0.86% | +17.04% | +108.44% | 491B | ||
| -0.25% | -3.60% | -3.36% | -10.05% | 360B | ||
| -0.51% | -3.36% | +17.68% | +41.50% | 312B | ||
| -2.69% | +0.39% | -2.65% | +38.62% | 263B | ||
| -1.32% | -0.94% | +0.20% | -32.16% | 236B | ||
| -1.78% | -0.40% | +3.85% | +25.71% | 212B | ||
| -0.69% | -4.70% | +4.77% | +18.92% | 204B | ||
| -0.68% | -0.85% | +2.46% | +29.72% | 149B | ||
| Average | -0.76% | -0.28% | +3.73% | +39.42% | 297.12B | |
| Weighted average by Cap. | -0.62% | -0.47% | +12.72% | +81.97% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 46.34B 48.79B 43.05B 38.2B 69.16B 4,142B 76.45B 535B 197B 1,700B 183B 179B 7,412B | 46.56B 49.01B 43.25B 38.38B 69.48B 4,161B 76.81B 538B 198B 1,708B 184B 180B 7,447B |
| Net income | -27.55M -29.01M -25.59M -22.71M -41.12M -2.46B -45.45M -318M -117M -1.01B -109M -107M -4.41B | 2.33B 2.46B 2.17B 1.92B 3.48B 208B 3.85B 26.92B 9.93B 85.53B 9.22B 9.02B 373B |
| Net Debt | 32.31B 34.02B 30.01B 26.63B 48.22B 2,888B 53.3B 373B 138B 1,185B 128B 125B 5,168B | 29.31B 30.85B 27.22B 24.16B 43.74B 2,619B 48.35B 338B 125B 1,075B 116B 113B 4,688B |
More financial data
* Estimated data
Employees
94,245
Sector
Pharmaceuticals
Calendar
2025-03-05
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-10 | 20.28 € | +0.27% | 3,184,031 |
| 24-12-09 | 20.23 € | +1.07% | 3,654,019 |
| 24-12-06 | 20.02 € | +2.64% | 4,615,729 |
| 24-12-05 | 19.50 € | +1.25% | 3,354,823 |
| 24-12-04 | 19.26 € | +0.14% | 3,193,159 |
Delayed Quote Xetra, December 10, 2024 at 11:35 am EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
20.28EUR
Average target price
28.00EUR
Spread / Average Target
+38.06%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock